Senti Biosciences is a team of engineers, scientists, and entrepreneurs on a mission to leverage synthetic biology to treat the most pressing diseases. They have pioneered new technology platforms to design synthetic gene circuits for adaptive cell and gene therapies. Their recently completed Series A round of funding will be used to further the growth of their scalable therapeutic design platform and advance therapeutic candidates towards the clinic.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/27/18 | $53,000,000 |
Allen & Company Amgen Business Development Goodman Capital LifeForce Capital Lux Capital Menlo Ventures Nest.Bio Ventures Omega Funds Pear Ventures | undisclosed | |
| 01/06/21 | $105,000,000 | Series B |
Amgen Business Development Intel Capital Leaps by Bayer  Lux Capital Matrix Partners Mirae Asset Venture Investment New Enterprise Associates Ridgeback Capital Management | undisclosed |
